The Group's principal activity is to develop and commercialize therapeutic products for the treatment of cancer. Its cancer vaccines are designed to stimulate the immune system to attack cancer cells, while its small molecule compounds are designed to inhibit the activity of specific cancer-related proteins. The Group is advancing its product candidates through in-house development efforts and strategic collaborations with leading pharmaceutical companies.
Alacra Alerts:
Receive alerts on the latest reports on Oncothyreon Inc.
Subscribe to Alacra Alerts via RSS and never miss the latest research on your favorite companies. Just click the images above to add the feed directly to your favorite newsreader.
